Effects of Gambisan in overweight adults and adults with obesity
A retrospective chart review

Dae-Hyun Jo, KMD, MA, Seunghoon Lee, KMD, PhD, Jae-Dong Lee, KMD, PhD*

Abstract
Objective: A retrospective chart review was conducted to explore the effect of Gambisan, a granular extract of novel herbal medicine, for short-term (≤16 weeks) weight loss in adults who are overweight and those with obesity.

Methods: Outpatients of Kyung Hee University Korean Medicine Hospital (Seoul, Korea) who took Gambisan and underwent bioelectric impedance analysis were selected (Jan 2011 to Dec 2015); their electronic medical records and clinical charts were retrospectively reviewed. The effectiveness of Gambisan was primarily evaluated by comparing body weight (BW) at baseline and endpoint, using paired t-tests; the safety of Gambisan was evaluated on the basis of adverse events (AEs) experienced by patients.

Results: Two hundred five patients were included in this study. The study population exhibited a significant reduction in BW (73.69 ± 14.49 kg to 69.01 ± 13.20 kg, P < .001) as well as percentage body fat (37.38 ± 5.38% to 34.50 ± 6.83%, P < .001). Moreover, 111 (54.1%) patients achieved modest weight loss (≥5%), while 35 (17.1%) achieved ≥10% weight loss. Furthermore, Gambisan induced significant reduction of BW in all subgroups (body mass index, sex, prescribed duration, and dosage). Among 139 patients with available data, 79 (56.8%) reported loss-of-appetite. In addition, 120 (mostly mild) AEs were reported in 69 (49.6%) patients, and the most frequent AEs were nausea, palpitation, and insomnia.

Discussion: Despite limitations in interpreting the results of this retrospective medical record review, Gambisan induced statistically and clinically meaningful weight loss with a tolerable level of AEs. Based on the findings of this review, further well-designed clinical trials are warranted.

Abbreviations: AEs = adverse events, BMI = body mass index, BW = body weight, CTCAE = Common Terminology Criteria for Adverse Events, KHUKMH = Kyung Hee University Korean Medicine Hospital, MWL = modest weight loss, OCS = order communicating system, PBF = percentage body fat.

Keywords: retrospective chart review, Traditional Korean Medicine, herbal medicine, Gambisan, weight loss, obesity, overweight

1. Introduction
It has been estimated that 1.9 billion people globally are overweight, of which 650 million exhibit obesity. In South Korea, the rate of obesity in the population has been constantly increasing since 1998 and is now estimated to be 37.9% in men and 25.9% in women. Because obesity induces a battery of complications, from hypertension and type 2 diabetes to deadly stroke and coronary syndromes, management of obesity has attracted significant attention. However, correcting dietary and exercise habits requires significant effort and often results in disappointing reward after behavioral modification; thus, pharmaceutical intervention has been highlighted as a complementary option. Although orlistat, sibutramine, phentermine, and rimonabant have been prescribed for individuals with obesity, they have a limited weight-maintaining effect or an unfavorable risk-benefit ratio, with various adverse events (AEs) or harmful impact. This has prompted demands for novel agents that are based on components from natural plants or herbal decoctions for weight loss. Subsequently, some clinical reports and randomized controlled trials investigating these materials have been published.

Gambisan is an extract of an herbal decoction that was newly developed by Kyung Hee University Korean Medicine Hospital (KHUKMH; Seoul, Korea) in 2009; since then, ≥10 million packs have been prescribed to the target population: patients who are overweight and those with obesity. The recipe was modified from Wolbigachul-tang, which is recorded in the classic traditional Chinese medicine literature, “Keumgueoryak”; the original prescription was used to treat edema and, more recently, obesity. In 3T3 adipocytes from obesity-induced mice,
Gambisan and its 3 major components – *Ephedra intermedia Schrenk, Atractylodes lancea (Thumb.) DC.*, and *Thea sinensis L.* – suppressed adipogenesis depending on concentration, and the compound demonstrated better results compared with its individual components. In a retrospective chart review involving 28 patients with musculoskeletal pain, Gambisan significantly relieved pain followed by weight reduction. However, there have been no practical studies focusing on its effectiveness for weight loss. Therefore, the present study investigated its weight-reducing effect, as well as reported AEs by reviewing the medical records of adults treated with Gambisan who were overweight, as well as those with obesity.

2. Methods

2.1. Study design and setting

This study reviewed the medical records of outpatients who were overweight and those with obesity in KHUKMH who were prescribed Gambisan between January 2011 and December 2015. The research plan of this retrospective chart review was approved by institutional review board of KHUKMH (KOM-CIRB-160418-HR-016). The data were collected and analyses were conducted until May 2016. One researcher (DHJ) fully reviewed the following sources for data: the Order Communicating System (OCS)—a computerized archive of individual management that records diagnosed disease names, diagnostic tests and therapeutic interventions in a form of a code for billing purposes; and scanned clinical charts of each patient on which the medical information and the progress of the patient were manually recorded, and the printed reports of bioelectrical impedance analysis were present. Given the retrospective nature of this study and the use of anonymized patient data, requirements for informed consent were waived.

2.2. Patients

Outpatients who had ever been prescribed Gambisan that is registered in the OCS as code “HH911G”, and met the following criteria were eligible for the present review: the reports of bioelectric impedance analysis (InBody 720, InBody Co., Seoul, Korea) that is registered in the OCS as code “35BL3” were recorded more than 2 times in an interval of 15 to 128 days; age ≥18 years; body mass index (BMI) ≥23 kg/m²; and compliance ≥70%. In this study, the operational definition of compliance according to the researchers was drawn by dividing the number of days on which Gambisan was prescribed by the total number of days between baseline and endpoint; this was represented as percentage (%).

Patients with any of the following conditions were excluded: taking anti-obesity medication within the previous 6 months; bariatric surgery within the previous 60 months; any medication considered to impact weight (newly applied or changed within the previous 3 months); change in smoking habits within the previous 3 months; psychological eating disorder; breast feeding the previous 3 months; change in smoking habits within the previous 6 months; taking anti-obesity medication within the previous 3 months; psychological eating disorder; breast feeding the previous 3 months; and compliance ≥70%.

2.3. Intervention

Gambisan, a novel granular herbal extract, was officially licensed in Korea in January 2010 (Registration No.: 4008119620000), and quality control of the preparation processes of each of the herbs were conducted according to Korean Good Manufacturing Practice. Comprising this formulation are the herbal part of *Ephedra intermedia Schrenk, Gypsum Fibrosum*, and the rhizome part of *Atractylodes lancea DC* and the leaf part of *Thea sinensis L.* Their voucher specimens are stored at KHUKMH. Well-ground ephedra, gypsum and atractylodes are mixed in a ratio of 3:4:2 (w/w) and extracted 2 times by boiling with distilled water. In succession, this extracted liquid undergoes evaporation and lyophilization. Thea separately undergoes an identical process. These 2 powders are mixed in a ratio of 1:0.8 (w/w) into the final product after several homogenizing steps. The standard compound consists mainly of ephedrine, epigallocatechin-3-gallate, and caffeine, with an expected content of 20 mg, 110 mg, and 65 mg, respectively, per 3 g pack. Subjects routinely took a pack of Gambisan 2 to 5 times daily, before each meal. On the first visit, practitioners gave identical information to patients by providing a booklet with brief usual care advice on diet and exercise habits, and with the list of expected AEs including nausea, palpitation, and sleep disturbance, among others in order to prevent patients from feeling anxious and suspicious about intervention due to AEs.

2.4. Weight-reducing effect

The primary outcome measure of this study was change in the mean BW of the study population, which was assessed with the reports of the InBody device and analyzed using paired t-tests. Change in the mean percentage body fat (PBF) was also reviewed. In addition, percentage change (%) in BW and percent point change (%) in PBF of a single patient were operationally defined as the magnitude of effectiveness and were entered into multiple regression models as dependent variables. For practitioners, the adequacy of a specific pharmaceutical intervention is determined by whether it leads to modest weight loss (MWL, i.e., 5% to 10%), as well as whether it reduces the risks for metabolic and cardiovascular diseases—or improves comorbidities—within 3 months. In this analysis, the proportion of patients who lost more than 5% of BW at baseline was mainly reported in the context of MWL; the proportion of patients who showed ≥3% and ≥10% of weight reduction was also assessed.

2.5. Subgroup analyses

The following subgroup analyses were conducted according to the conditions of Gambisan prescription:

1. body mass index⁻ [23 kg/m² ≤ BMI ≤ 25 kg/m²]: overweight, 25 kg/m² ≤ BMI ≤ 30 kg/m²: obese I, BMI ≥ 35 kg/m²: obese IIa, 35 kg/m² ≤ BMI: obese IIb);
2. sex;
3. prescribed duration (4 weeks: 15 to 42 days, 8 weeks: 43 to 70 days, 12 weeks: 71 to 98 days and 16 weeks: 99 to 126 days); and
4. daily dose (1 time, 2 times, 3 times, 4 times, and 5 times). Paired t tests were conducted in each of the subgroups in order to identify any conditions under which Gambisan failed to induce differences in BW (kg) and PBF (%).
2.6. Self-reported symptoms

Self-reported symptoms, such as AEs and loss of appetite, were collected by reviewing clinical charts and conducting telephone interviews. Practitioners conducted telephone interviews on a yearly basis with outpatients who completed the full course of intervention in the year, for the purpose of understanding patients’ experience with a main focus on the symptoms associated with Gambisan, experienced at least once by the patients. The patients were asked about loss of appetite and the presence of any unfavorable events and specific symptoms — a list of potential AEs was provided whenever necessary. Measures taken to manage the AEs, their impact, and the results were additionally recorded to grade each AE according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.14. The frequencies of loss of appetite and AEs were reported and the severities of those AEs were described using grade classification.

2.7. Statistical analysis

Statistical analyses were performed using PASW Statistics version 18.0 (SPSS Inc., Chicago, IL). Continuous variables are presented as mean ± standard deviation (SD) and categorical variables are presented as number and percentage. To compare mean BW and PBF at endpoint with baseline, a paired t test or a Wilcoxon rank test was performed according to whether the data were normally distributed or skewed; P ≤ .05 was considered to be statistically significant.

Multiple linear regression analyses were performed to investigate whether any of conditions of Gambisan prescription (BMI, sex, days of intervention and daily dosage) exercised influence on change in BW (%) or PBF (%p). Age was also considered to be a confounding factor. Variables with a variance inflation factor ≥ 2.5 were regarded to be collinear and were excluded from the regression procedure. Non-significant factors (i.e., P > .05) were sequentially eliminated from the model until all existing factors significantly explained the variances of the dependent variables.

3. Results

3.1. Study population

From the OCS archive, 587 patient IDs that had more than one of the code “HH911G” and more than 2 of the code “35BL3” between January 2011 and December 2015, were extracted. Satisfying the inclusion criteria, 205 patients were finally confirmed as the study population after screening their records (Fig. 1). Among the study population, females were dominant (n = 172 [83.9%]). Mean weight was 73.69 ± 14.49 kg and mean BMI was 28.17 ± 3.67 kg/m². On average, subjects took Gambisan 3.3 times daily (range, 1–5 times daily) for 60.7 days (range, 16–126 days). Detailed demographic and clinical characteristics of the study population are summarized in Table 1.

3.2. Weight-reducing effect

After the intervention, a significant reduction in mean BW (73.69 ± 14.49 kg to 69.01 ± 13.20 kg [6.15%]; P < .001) was observed. Mean PBF was also significantly decreased from 37.38 ± 5.38% to 34.50 ± 5.83% ([2.88%]; P < .001). In the context of MWL, 111 (54.1%) patients showed ≥ 5% of BW reduction, while 154 (75.1%) lost ≥ 3%, and 35 (17.1%) lost ≥ 10% (Table 2).

3.3. Subgroup analyses

Individual patients were assigned to 1 of 4 subgroups based on their weight status. All overweight (P < .001; 5.61%), obese I (P < .001; 5.83%), obese IIa (P < .001; 7.50%) and obese IIb (P = .008; 6.41%) groups exhibited significant reduction in mean BW (Table 3). Changes in PBF were also statistically meaningful at endpoint, and the proportion of patients who achieved MWL was 48.6% (overweight), 55.8% (obese I), 51.2% (obese IIa) and 66.7% (obese IIb) (Fig. 2A). Both females and males demonstrated significant decrease in mean BW (female: P < .001)

Table 1

| Characteristic                      | Value  | Variable | Value  |
|-------------------------------------|--------|----------|--------|
| Number (f/M)                        | 205 (172/33) | Compliance (%) | 94.26 ± 8.19 |
| Age (yr)                            | 45.7 ± 13.4 | Smoking (%M) | 14 (6.8) |
| Height (cm)                         | 161.19 ± 7.83 | Alcohol (%M) | 70 (34.2) |
| Weight (kg)                         | 73.69 ± 14.49 | Chronic Conditions (%M) | 39 (19.0) |
| BMI (kg/m²)                         | 28.17 ± 3.67 | Hypertension | 30 (14.6) |
| Body fat mass (kg)                  | 27.69 ± 5.75 | Diabetes | 11 (5.4) |
| Body fat (%)                        | 37.38 ± 5.38 | Dyslipidemia | 30 (14.6) |
| Regimen of Gambisan Coronary Diseases, 2 | 1.0 | Compliance (%) | 94.26 ± 8.19 |
| Duration (days)                     | 60.7 ± 29.5 | Compliance (%) | 94.26 ± 8.19 |
| Dosage (times)                      | 3.3 ± 0.6 | Stroke, h/o | 4 (2.0) |
|                                     |         | Cancer, h/o | 10 (4.9) |

Data presented as mean ± S.D. unless otherwise indicated. BMI = body mass index, F = Female, M = Male.

* Compliance (%) = (days Gambisan prescribed / (days from baseline to endpoint) x 100 (%).
| Variable                  | Endpoint | Baseline – endpoint | % (p) change |
|--------------------------|----------|---------------------|--------------|
| Weight (kg)              | 69.01 ± 12.20 | 4.68 ± 3.72 2       |              |
| Body fat (%)             | 34.50 ± 5.83  | 2.88 ± 2.82    2    |              |
| % < 5%                   | 154 (75.1%) | 111 (64.1%)       | 35 (17.1%)   |

Data presented as Mean ± SD unless otherwise indicated.

1 P < .001 (Paired t test).

2 [6.42%]; male: P < .001 [6.10%] and PBF (Table 3). Additionally, the success rate of MWL was 55.2% in females and 48.5% in males (Fig. 2B). In subgroup analysis according to the length of treatment, mean BWs were significantly changed in the 4 week group (P < .001 [3.72%]), the 8 week group (P < .001 [6.67%]), the 12 week group (P < .001 [8.36%]) and the 16 week group (P < .001 [8.48%]) as well as mean PBFs (Table 3). The success rates of MWL of these subdivisions were 21.1%, 63.9%, 86.1%, and 78.1%, respectively (Fig. 2C). Although the daily consumption of Gambisan ranged from 1 to 5 doses, practitioners rarely recommended patients to take Gambisan 1 time (1 patient) or 5 times (2 patients) per day; thus, these groups were excluded from analysis. In the context of BW reduction, the groups of the 2 time (P < .0015 [4.61%]), 3 time (P < .001 [5.63%]) and 4 time (P < .001 [7.28%]) generated significant changes, and 60%, 45.9%, and 67.1% of subjects in each subdivision exhibited MWL (Fig. 2D).

3.4. Multiple linear regression analysis

To assess correlations between the conditions of Gambisan prescription (i.e., BMI, sex, treatment duration and dosage) and the magnitude of BW reduction (%), multiple regression analysis was performed (Table 4). Age was additionally considered to be a confounding factor. Following the elimination procedure, female sex (P = .936) and baseline BMI (P = .140) were progressively removed because they were not significant contributors to the change in BW. Days of treatment (β = .066, P < .001), daily dosage (β = .098, P = .042), and age (β = −.087, P < .001) demonstrated significance in explaining variations of outcomes and thus were retained in the final regression equation model (R2 adjusted = .326). An identical procedure was executed to explore the influence of conditions on changes in PBF (Table 4). A backward elimination procedure discarded the variables of baseline BMI (P = .611), female sex (P = .146) and age (P = .129), while days of treatment (β = .043, P < .001) and daily dosage (β = −.782, P = .013) were retained in the significant final model (R2 adjusted = .231).

3.5. Self-reported symptoms

Among the study population, data from 139 patients clearly demonstrated whether the patients experienced loss of appetite or any AEs. Seventy-nine (56.8%) subjects had ever lost appetite during the treatment period. A total of 120 AEs were reported in 69 (49.6%) patients, and nausea (18.7%), palpitation (13.7%), insomnia (10.8%), dry mouth (9.4%), constipation (7.2%), stomach pain (4.3%), and dyspepsia (3.6%) were observed in ≥5 patients (Table 5). Most AEs were classified as grade 1 according to the CTCAE criteria. There were 6 AEs that were regarded as moderate (grade 2); 1 was urinary retention, which led to altering the course of medical treatment of benign prostate hypertrophy, another was dry mouth requiring copious amounts of water; and the other 4 consisted of moderate difficulty falling asleep that did not require taking medication.

4. Discussion

Since its development in 2009, millions of packs of Gambisan have been prescribed in KHUKMH for weight loss. By retrospectively reviewing and analyzing the accumulated medical records on an electronic database and scanned clinical charts, the present study tried to explore the effectiveness of Gambisan in weight loss. The results showed that Gambisan induced significant reduction in the mean BW and mean PBF of 205 individuals who were overweight or exhibited obesity. Analysis revealed an average weight loss of 4.68 ± 3.72 kg (6.15%) among the study population following 60.7 days of treatment with Gambisan. This result represents a higher degree of weight loss than previously shown in 2 retrospective studies (phentermine71 orlistat11) on existing drugs and one non-RCT (Bangpoongtongungsans116) and one pilot-RCT (TJ00117) on herbal medicine, thus may potentially be considered clinically...
meaningful. In the context of modest weight loss, it is notable that our observed proportion of the study population that lost 5%/10% of BW is comparable to results in the literature, including a meta-analysis, which summarizes the results of RCTs investigating the use of orlistat, sibutramine, or rimonabant over 1 or 2 years (Gambisan: 54.1%/17.1% vs orlistat: 54%/26%; vs sibutramine: 55%/28%; vs rimonabant: 51%/26%).[18]

Subgroup analyses were performed to assess the impact of Gambisan on weight loss under various conditions. Practitioners at the KHUKMH recommended monthly follow-ups for 3 to 4 months during this pharmaceutical intervention,[7] and the duration of treatment was categorized into 4 subgroups. The agent induced significant changes in mean BW (kg) and PBF (%) in all pairs classified according to demographic characteristics such as weight status and sex. Moreover, the effect size was not considerably different between subgroups according to change in BW (%), PBF (%p), and the proportion of subjects with MWL, which was though not statistically reviewed. This aspect was identified in the multiple regression procedure that eliminated those 2 factors for being not significant in explaining the dependent variable, all of which indicated this novel herbal medicine could be extensively applied to the overweight population. In terms of treatment, significant reduction in BW (kg) and PBF (%) was observed throughout all pairs based on treatment duration and daily dose of Gambisan. It is noteworthy that the impact was not even, but increased in the magnitude of BW (%) and PBF (%p) change over the subdivisions, which was also not statistically verified. Moreover, this aspect was statistically confirmed by the multiple regression models, which accepted linear correlations of the variables of treatment days and daily dose with the dependent variables. Because the extracted data were not thoroughly controlled in a prospective manner, interpretation of these results is inherently preliminary. However, researchers suggest that practitioners could consider applying this

---

**Table 4**

Multiple regression analyses of the impact of conditions of Gambisan prescription and of confounding factor (age) on body weight and percentage body fat reduction by the backward elimination procedure.

|                          | % Change in body weight | %p Change in percentage body fat | r² Adjusted | N |  
|--------------------------|-------------------------|----------------------------------|------------|---|
| (Constant)               | 3.158                   | 1.919                            | .101       | .326, N = 202 |  
| Days of treatment        | .006                    | .008                             | .470       | .000 |  
| Daily dosage             | .903                    | .445                             | .122       | .042 |  
| Age                      | -.087                   | .019                             | -.280      | .000 |  

R² Adjusted = .326, N = 202

1 Female sex (P = .936) and baseline body mass index (BMI) (P = .140) were progressively eliminated.

2 Baseline BMI (P = .611), female sex (P = .146) and age (P = .129) were progressively eliminated.

3 Dosages of 1 time (1 patient) and 5 times (2 patients) groups were excluded because the numbers of their sample were smaller than the number of variables. Residual plots were not controlled.
novel herbal medicine for at least 12 weeks and up to 4 times per day, to achieve sufficient effect, provided that any issues concerning AEs are trivial.

For decades, studies to discover the potential of plants and their phytochemicals in controlling obesity have been conducted. These focused on several promising modes of actions such as inhibition of lipase activity, appetite suppression/satiety induction, thermogenesis, regulation of lipid metabolism, and accumulation by inhibiting the activity of pancreatic lipase and thermogenesis, mainly in brown adipose tissue via the sympathetic nervous system. In terms of severity of AEs, 6 out of 120 AEs that were associated with Gambisan use were classified as moderate, which meant that the patients experienced some degree of discomfort and in some cases, needed to change their medication for their existed comorbidity. All of these symptoms disappeared within a few days to weeks. Presented in Table 5 without being mentioned in the result part is one case of a patient who underwent cholecystectomy (grade 3 [severe]) due to gallstone development.

The occurrence of AEs was common in this study; however, they were comparable to those of other anti-obesity drugs (Gambisan: 49.6% vs orlistat [5,31,32]: 78% to 91%, sibutramine [13-35]: 49% to 79%, phentermine [17,36,37]: 30% to 96%).

The most frequent AEs included nausea, palpitation, insomnia, dry mouth, and constipation, and these AEs were consistent with those reported by previous randomized controlled trials on herbal mixtures with ephedrine/caffeine [38-41]. Over the past few decades, controversies regarding dietary supplements containing ephedrine have emerged. [42,43]. However, a series of investigations [38-41] have reported that low-dose ephedrine, alternatively enhanced with caffeine, did not significantly induce more unfavorable effects compared with placebo control. Furthermore, the study population in the present study took the same unfavorable effects compared with placebo control. Furthermore, the study population in the present study took the same unfavorable effects compared with placebo control.

Aside from the occurrences of AEs, there were unavoidable limitations to this study given that it was a retrospective chart review. First, the study population was restricted to patients who were consistently prescribed Gambisan and who underwent bioelectric impedance analysis measurement more than 2 times. Those with low compliance due to unsatisfactory improvement or AEs were more likely to be excluded from the review, which likely introduced selection bias in this study. Second, in the outpatient clinic, patients who visit KHUKMH with the purpose of weight reduction have been routinely prescribed Gambisan, or an herbal medicine of similar composition. Thus, it was impossible to generate a comparative control group for the study from available databases, such that the results of this preliminary study are not confirmatory. Third, limitations in the electronic medical charts provided incomplete

---

Table 5

| Symptom                         | Loss of appetite | Patients experienced AEs | \( \frac{79 (56.8)}{69 (49.6)} \) | Total Mild Moderate/Severe |
|---------------------------------|------------------|--------------------------|-----------------------------------|-----------------------------|
| Nausea                          | 26 (18.7)        | 26                       | -/-                               | \( \frac{7 (5.0)}{5 (3.6)} \) |
| Palpitation                     | 19 (13.7)        | 19                       | -/-                               | \( \frac{2 (1.4)}{2 (1.4)} \) |
| Insomnia                        | 15 (10.8)        | 11                       | 4/1                               | \( \frac{79 (56.8)}{79 (56.8)} \) |
| Dry mouth                       | 13 (9.4)         | 12                       | 1 1/2                             |                             |
| Constipation                    | 10 (7.2)         | 10                       | -/-                               | \( \frac{4 (2.9)}{4 (2.9)} \) |
| Stomach pain                    | 6 (4.3)          | 6                        | -/-                               | \( \frac{79 (56.8)}{79 (56.8)} \) |
| Dyspepsia                       | 5 (3.6)          | 5                        | -/-                               | \( \frac{2 (1.4)}{2 (1.4)} \) |
| Dizziness                       | 4 (2.9)          | 4                        | -/-                               | \( \frac{79 (56.8)}{79 (56.8)} \) |
| Irritability                    | 3 (2.2)          | 3                        | -/-                               | \( \frac{4 (2.9)}{4 (2.9)} \) |
| Urinary frequency               | 3 (2.2)          | 3                        | -/-                               | \( \frac{79 (56.8)}{79 (56.8)} \) |
| Vomiting                        | 3 (2.2)          | 3                        | -/-                               | \( \frac{4 (2.9)}{4 (2.9)} \) |
| Alopecia                        | 2 (1.4)          | 2                        | -/-                               | \( \frac{79 (56.8)}{79 (56.8)} \) |
| Fatigue                         | 2 (1.4)          | 2                        | -/-                               | \( \frac{79 (56.8)}{79 (56.8)} \) |
| Unpleasant taste                | 1 (0.7)          | 1                        | -/-                               | \( \frac{79 (56.8)}{79 (56.8)} \) |
| Others                           | 7 (5.0)          | 5                        | 1/1†                              | \( \frac{79 (56.8)}{79 (56.8)} \) |

Total number of AEs: 120

AEs = adverse events.

1. The grade of each AE was classified according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

2. All four cases had moderate difficulty falling asleep that did not require taking medication.

3. Cephalic voice was needed but either alteration of food intake or rescue medication were not required.

4. Unpleasant taste was not defined in the CTCAE v4.03.

5. Others: Agitation, gall bladder stone, hot flushes, hyperchloremia, stiffness, tremor and urinary retention.

6. The resulting urinary retention required a change in the medication that were being taken for benign prostate hypertrophy.

7. Cholecystectomy was required due to gallbladder stone which was, however, unlikely related to Gambisan.
data regarding patients’ economic status and dietary and exercise habits, all of which are important obesity-related factors. Finally, to determine the detailed properties of Gambisan, laboratory and anthropometric parameters related to energy and fat metabolism must be investigated. In the context of the above limitations, a double-blinded, randomized, placebo-controlled, phase 2 study is planned based on the findings of this study; this has been registered by the authors of the present study.

In conclusion, the present study found that Gambisan was effective for weight loss regardless of prescription conditions and its safety was competitive in terms of AEs. However, the results should be interpreted with caution because the study design was not confirmative and had several limitations. Further well-designed, prospective studies are required to confirm the findings of this study with regard to the promising novel anti-obesity herbal medicine.

Acknowledgments

The authors are indebted to Dr. Hyunho Kim for his helpful comments on statistical analyses.

Author contributions

This study project was administrated and supervised by the corresponding author, Jae-Dong Lee. Seunghoon Lee and Dae-Hyun Jo conceived and designed the study. DHJ transformed the data from medical records and conducted the statistical analyses. DHJ drafted the report and SL wrote the final manuscript. Thus, DHJ and SL contributed equally. All authors participated in the discussion and the critical revisions of the initial article and approved to submit the final manuscript. Thus, DHJ and SL contributed equally. All authors participated in the discussion and the critical revisions of the initial article and approved to submit the final manuscript.

Conceptualization: Dae-Hyun Jo, Seunghoon Lee.

Formal analysis: Dae-Hyun Jo.

Methodology: Dae-Hyun Jo, Seunghoon Lee.

Project administration: Jae-Dong Lee.

Supervision: Jae-Dong Lee.

Writing – original draft: Dae-Hyun Jo.

Writing – review & editing: Dae-Hyun Jo, Seunghoon Lee, Jae-Dong Lee.

References

[1] World Health Organization . Obesity and Overweight Fact Sheet Updated 16 February, 2018. [??], Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ [access date February 8, 2019]
[2] Shin HY, Kang HT. Recent trends in the prevalence of underweight, overweight, and obesity in Korean adults: the Korean National Health and Nutrition Examination Survey from 1998 to 2014. J Epidemiol 2017;27:413–9.
[3] Kang G, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 2012;36:13–25.
[4] Washburn RA, Szabo AN, Lambourne K, et al. Does the method of weight loss effect long-term changes in weight, body composition or chronic disease risk factors in overweight or obese adults? A systematic review. PLoS One 2014;9:e109849.
[5] Davidson MH, Hauptman J, DeGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235–43.
[6] James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:301–17.
[7] Kim HO, Lee JA, Suh HW, et al. Postmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity. Korean J Fam Med 2013;34:298–306.
[8] Korean Society of Study of Obesity . Guidelines for management of obesity. 2014;[?], Available at: http://www.konso.or.kr/general/board/ list.html?code=general_03 [access date February 8, 2019]
[9] Huang MJ, Shin HD, Song MY. Literature review of herbal medicines on treatment of obesity since 2000 - mainly about ephedra herba. J Soc Kor Med Obes Res 2007;7:39–54.
[10] Natarajan Ranjbar S, Nayebi N, Larijani B, et al. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol 2009;15:3073.
[11] Kwak HY, Kim JH, Seon JL. The effects and adverse events of Gamowulbaguchalang on the changes of body composition and musculoskeletal pain in 28 overweight patients: A retrospective observational study. Acupuncture 2011;28:103–10.
[12] Kang JW, Nam DW, Kim KH, et al. Effect of Gambisan on the inhibition of adipogenesis in 3T3-L1 adipocytes. Evid Based Complement Altern Med 2013;2013:11.
[13] Park SJ, Park JS, Cheon C, et al. A pilot study to evaluate the effect of Taecumjowi-tang on obesity in Korean adults: study protocol for a randomized, double-blind, placebo-controlled, multicentre trial. Trials 2012;13:33–42.
[14] National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) v4.03. 2019;[?], https://ctep.cancer.gov/protocoldevlopment/electronic_applications/cctc.htm#ctc_40. Accessed 8 February 2019.
[15] An SM. The effect of orlistat on weight reduction in Korean obese patients [Master’s thesis]. Seoul: Sook Myung University, 2001.
[16] Shin DH, Choi J, Lee H. Clinical study of Bangoongtongsuigan on body weight change in subjects with obesity. Herbal Formula Sci 2008;16:133–44.
[17] Park S, Nahnkkoong W, Cheon C, et al. Efficacy and safety of Taecumjowi-tang in obese Korean adults: a double-blind, randomized, and placebo-controlled pilot trial. Evid Based Comp Altern Med 2013;2013:10.
[18] Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194–9.
[19] de Freitas LMJr, de Almeida EBJr. Medicinal plants for the treatment of obesity: ethnopharmacological approach and chemical and biological studies. Am J Transl Res 2017;9:2050–64.
[20] Balaji M, Ganjyai MS, Kumar GH, et al. A review on possible therapeutic targets to contain obesity: the role of phytochemicals. Obes Res Clin Pract 2016;10:365–80.
[21] Casacchia T, Scavello F, Rocca C, et al. Leopoldia comosa prevents metabolic disorders in rats with high-fat diet-induced obesity. Eur J Nutr 2018;58:965–79. https://doi.org/10.1007/s00394-018-1609-1.
[22] Olduni S, Roque MW, Camilleri M, et al. Effect of aliciata on satiation, appetite, gastric function and selected gut satiety hormones in overweight and obesity. Obesity 2010;18:1579–94.
[23] PÉrez-Jiménez A, Rufino-Palomares EE, Fernández-Gallego N, et al. Target molecules in 3T3-L1 adipocytes differentiation are regulated by malandin, a natural triterpene from Olea europaea. Phytomedicine 2016;23:1301–11.
[24] Ramsey JJ, Colman RJ, Swick AG, et al. Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. Int J Nutr 1986;51:81.
[25] Hackman RM, Havel PJ, Schwartz HJ, et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. Int J Obes 2006;30:1545–56.
[26] Horton TJ, Geissler CA. Post-prandial thermogenesis with ephedrine, caffeine and aspirin in lean, pre-disposed obese and obese women. Int J Obes Relat Metab Disord 1996;20:91–7.
[27] Dulloo AG, Miller DS. The thermogenic properties of ephedrine/ methyllxanthine mixtures: human studies. Int J Obes 1986;10:467–81.
[28] Astrap A, Toubro S, Cannon S, et al. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind placebo-controlled study. Metabolism 1991;40:523–9.
[29] Dulloo AG, Seydoux J, Gararder L. Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. Int J Obes 1991;15:317–26.
[30] Grove KA, Lambert JD. Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J Nutr 2010;140:446–53.
[31] Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004; 27:153–61.

www.md-journal.com
Dias T, Chambel P, Carvalheiro M, et al. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia. Rev Port Cardiol 2009;28:1361–74.

Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:1331–9.

Porter JA, Rachel MA, Conner DA, et al. The long-term outcomes of sibutramine effectiveness on weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004;10:369–76.

Park HS, Kim KS, Kim BT, et al. Double-blind, randomized, multi-center, comparative clinical trial of sibutramine mesilate with sibutramine hydrochloride for evaluating efficacy and safety in obese patients. Korean J Obes 2008;17:82–90.

Choi CJ, Kim KS, Kim SR, et al. Double-blind, parallel-group, placebo-controlled multi-center clinical trial for evaluating the efficacy and safety of phentermine hydrochloride in obese patients. Korean J Obes 2005;14:155–62.

Kim KK, Cho HJ, Kang HC, et al. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006;47:614–25.

Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guanara for weight loss: a randomized, double-blind trial. Intern J Obes 2001;25:316–24.

Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized study and efficacy trial. Intern J Obes 2002;26:591–604.

Greenway FL, De Jonge L, Blanchard D, et al. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obes Res 2004;12:1152–7.

Coffey CS, Steiner D, Baker BA, et al. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes 2004;28:1411–9.

Shekelle P, Hardy M, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289:1537–45.

Kim HJ, Park JM, Kim JA, et al. Effect of herbal Ephedra sinica and Evodia rutacearpa on body composition and resting metabolic rate: a randomized, double-blind clinical trial in Korean premenopausal women. J Acupunct Meridian Stud 2008;1:128–38.

Kim HU, Ryu JY, Lee JO, et al. A systems approach to traditional oriental medicine. Nat Biotechnol 2015;33:264–8.

Clinical Research Information Service: Cheongju (Chungcheongbuk-do): Korea Centers for Disease Control and Prevention (Korea). Identifier KCT0002193: Efficacy and Safety of Hanslim for Obesity: A double-blinded, randomized, multicenter, multi-dose, placebo-controlled clinical trial. Available at: https://cris.nih.go.kr/cris/search/search_result_et01_kren.jsp?seq=7468&type=cr&view (Access date February 8, 2019).